Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated: November 2021

Nephrology


17. Faizan MK, McCracken C, Lieberman K, Leong T, Benfield MR. Practice patterns and outcomes of repository corticotropin injection (Acthar® Gel) use in childhood nephrotic


89. Sim JJ, Bhandari SK, Batech M, Hever A, Harrison TN, Shu YH, Kujubu DA, Jonelis TY, Kanter MH, Jacobsen SJ. End-stage renal disease and mortality outcomes across different

**Neurology**


**Neurology – HEOR**


216. Okimoto DM, Maru S, Numis AL, Panaccio MP, Wan GJ, Singh V. Clinical pathways leading to a diagnosis of infantile spasms using a claims database [AMCP abstract G23]. J Managed Care Spec Pharm. 2016;22(suppl 4-a):S70

217. Okimoto DM, Maru S, Numis AL, Panaccio MP, Wan GJ, Singh V. Clinical pathways leading to a diagnosis of infantile spasms using a claims database [AMCP abstract G23]. J Managed Care Spec Pharm. 2016;22(suppl 4-a):S70


Ophthalmology


231. Chen E, Reynolds H, Graham L. Ocular cicatricial pemphigoid treated with intramuscular corticotropin injections. JAAD Case Reports. 2020;6(5):450-452. Link


240. Scannell Bryan M, Sergott RC. Change in visual acuity and retinal structures following Repository Corticotropin Injection (RCI) therapy in patients with acute demyelinating optic neuritis: Improvement in low contrast visual acuity in both affected and contralateral eyes in a single-arm open-label study. *J Neurol Sci*. 2019;407:116505. [Link](#)


244. Sharon Y, Anesi SD, Martinez CE, Huang AJW, Foster CS, Chu DS. Repository corticotropin injection as an alternative treatment for refractory ocular mucous membrane pemphigoid. *Cornea*. 2021;[published online: May 2021]. [Link](#)


**Ophthalmology HEOR**


Pulmonology


Pulmonology – HEOR


326. Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. Ann Rheum Dis. 2015;74(suppl 2):1066-1067


328. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. Ann Rheum Dis. 2015;74(suppl 2):1066-1066


354. Wu A, June J. Case series: Comparison of repository corticotropin injection (H.P. Acthar Gel) versus glucocorticoids on bone density in SLE patients [ACR abstract 331]. *Arthritis Rheumatol*. 2017;69(suppl 10):452

355. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. *Arch Dis Child*. 1971;46(249):584-593. [Link](https://adc.bmj.com/content/46/249/584)

20


**Other**


387. Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? *Brain and Development*. 2001;7:647-648. [Link](#)


426. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. J Immunol. 2015;194(suppl 1):139.4-139.4


Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. *J Am Soc Nephrol*. 2012;23(suppl):725A.


456. Kongelbeck SR. Discharge planning for the child with infantile spasms. *J Neurosci Nurs*. 1990;No. 4:238-244. [Link](#)


470. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. Neurology. 2015;84(suppl 14):P2.189


473. Lisak R, Nedeelkoska L, Touil H, Bar-Or A, Benjamins J. Sigma 1 receptor and melanocortin receptor agonists protect oligodendroglia from death induced by products of B cells from multiple sclerosis patients. [ECTRIMS abstract P582]. Mult Scler. 2018;24(S2):280


485. Montroy T, Flechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


488. Obi O, Judson M, Maier L, Wells A, Baughman R. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients [ATS abstract A5609]. **Am J Respir Crit Care Med.** 2019;199:A5609.


495. Parr EJ. Hay fever treated with ACTH gel. **Clin Allergy.** 1976;6(5):479-486. [Link](#)


There is a vast body of clinical data in the peer-reviewed literature regarding the therapeutic use of Acthar® Gel (repository corticotropin injection). For more information, please contact our Medical Information Group by phone at 800.844.2830, by fax at 913.451.6409, or by email at medinfo@mnk.com